OP0129 Eudravigilance eval pregnancies exposed to non-TNF biologics compared certolizumab. Possible signal w/#vendolizumab: 3 cases of corpus callosum agenesis (2 Crohn’s, 1 UC, 2 assc w/ other CNS malformations). Belim did not show consistent pattern #EULAR2022 @rheumnow https://t.co/BNKaxu6G0c

Perez-Garcia et al. MTX effect on semen parameters. I still frequently get queries about this. 48 participants here. No significant effect! @RheumNow #EULAR2022 OP0131 https://t.co/33NG6isehm https://t.co/g7Xn33i96u

• EULAR Abstract Archive

BIOBADASER Registry data on comparative drug-dependent cancer risk in patients with prior cancer. 352 patients. 32 incident cancers (14 NMSC). No difference between agents, but wide CIs @RheumNow #EULAR2022 OP0138 https://t.co/NEZSL2AQhC https://t.co/EG0NflXXW6

• EULAR Abstract Archive

Spanish safety registry BIOBADASER 3.0: *9000+ pts with IMID treated w/ bio or tsDMARDS *352 pts w/ prior malignancy *32 incident malignancies -> 27 events/1000PY NO diff between ttmts in incidence or mortality but low number pts in non TNFi groups @RheumNow #EULAR2022 OP0138 https://t.co/8IyC6NdGCF

Million $$$ questions presented to Prof T Dorner: anifrolumab vs. belimumab for #SLE? He prefers belimumab d/t more data on multiple organ manifestations ^ it might be protective in pts w/ COVID19 infection. If skin dz is predominant, then anifrolumab #EULAR2022 @rheumnow

🚨 Study on MTX and male fertility Analysis of semen parameters in 🙋🏼‍♂️HC 🙋🏼‍♂️RA, PsA and PsO MTX naive 🙋🏼‍♂️Post MTX Reassuring data as NO significant effect of MTX was observed on several semen parameters. #EULAR2022 @RheumNow OP0131 https://t.co/Fq32lzAMAx

RABBIT registry and MACE in RA No difference between *JAKi (Tofa and Bari) and *TNFi in both unselected and high CV risks patients. 🧨 different than ORAL surveillance but Observational and overall Low incidence (28 events). #EULAR2022 @RheumNow OP0135 https://t.co/o8rngHrwQF

Low rates of hypersensitivity reactions (HSR) to #anifrolumab Pooled data MUSE & TULIP-1/-2 w/1100 pts: 👉1 anaphylaxis (0.15%) 👉12 HSR (3%) 👉43 infusion reaction (9%): N/V/headache 👉most easily treatable w/antihistamine, GCs, acetaminophen #EULAR2022 POS0708 @rheumnow